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Obstructive Sleep Apnea in Patients with Branch Retinal Vein 
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Purpose: Our study aimed to determine whether obstructive sleep apnea (OSA) is common among branch retinal 
vein occlusion (BRVO) patients without systemic risk factors using a Watch PAT-100 portable monitoring device. 
Methods: The study participants included consecutive patients with BRVO of less than 3 months duration with-
out any risk factors known to be associated with OSA (diabetes, coronary artery disease, stroke, hematologic 
diseases, autoimmune disease, etc.) except for hypertension. All patients underwent full-night unattended 
polysomnography by means of a portable monitor Watch PAT-100 device. The apnea-hypopnea index (AHI) 
was calculated as the average number of apnea and hypopnea events per hour of sleep, and an AHI score of 
five or more events was diagnosed as OSA.
Results: Among 19 patients (6 males and 13 females), 42.1% (8 of 19) had an AHI reflective of OSA. In the 13 
patients who had no concurrent illness, including hypertension, 30.8% (4 of 13) had positive test results for 
OSA; three of these patients were ranked as mild OSA, while one had moderate OSA. The OSA group had an 
average AHI of 12.3 ± 7.8, and the average AHI was 2.0 ± 0.9 in the non-OSA group. Although it was not sta-
tistically proven, we found that OSA patients experienced a more severe form of BRVO. 
Conclusions: We found a higher than expected rate of OSA in BRVO patients lacking concomitant diseases 
typically associated with OSA. Our findings suggest that OSA could be an additional risk factor in the patho-
genesis of BRVO or at least a frequently associated condition that could function as a triggering factor. 
Key Words: Branch retinal vein occlusion, Hypertension, Obstructive sleep apnea
Retinal vein occlusion (RVO) is the second most com-
mon retinal vascular disease after diabetic retinopathy and 
is an important cause of blindness and visual morbidity [1]. 
This condition affects males and females equally and oc-
curs most frequently between the ages of 60 and 70. The 
prevalence of RVO is 0.7%, and the 5-year incidence is 
0.8% [2]. The most common risk factors associated with 
branch retinal vein occlusion (BRVO) are systemic hyper-
tension, diabetes, hyperlipidemia, smoking, and age-relat-
ed atherosclerosis [3]. The interruption of venous flow in 
the eyes of BRVO patients aff licted with the aforemen-
tioned risk factors almost always occurs at a retinal arte-
riovenous intersection, where a retinal artery crosses a ret-
inal vein [4]. 
Obstructive sleep apnea (OSA) is the most common 
sleep-related breathing disorder, with an estimated preva-
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lence of 2% for women and 4% for men in the middle-aged 
population [5]. It is characterized by the repetitive com-
plete or partial collapse of the upper airway during sleep 
[6], which causes the cessation (obstructive apnea) or sig-
nificant reduction (obstructive hypopnea) of airflow. These 
respiratory events result in intermittent hypoxemia and 
hypercapnia, cortical arousals and surges of sympathetic 
activity [7]. OSA is an insidious disorder, and most patients 
are unaware of its symptoms; it is becoming increasingly 
recognized as an important cause of medical morbidity 
and mortality. The occurrence of OSA has been linked to 
increased cardiovascular morbidity and mortality, hyper-
tension, diabetes mellitus, atherosclerosis, and stroke, most 
of which are also common risk factors for BRVO [7-10]. 
Previous studies have shown an association between 
RVO and OSA [11,12]. However, these studies included 
both branch and central RVO patients, and there were not 
any exclusion criteria. In the present study, we aimed to 
determine whether OSA is common among patients with 
BRVO who do not have any systemic risk factors.
Materials and Methods 
This study was carried out in the ophthalmology clinic 
of the hospital of the Yonsei University College of Medi-
cine in Seoul, Korea. The institutional review board ap-
proved the ethical and methodological aspects of the inves-
tigation, and patients were required to provide signed 
written informed consent as a prerequisite for their partici-
pation. This study is also registered at ClinicalTrials.gov, 
number NCT01291862. Patients with BRVO of less than 3 
months duration were consecutively enrolled between 
April 2010 and March 2011. BRVO was assessed with an 
indirect ophthalmoscope by a retinal specialist and con-
firmed by fluorescein angiography (FA). Patients with in-
sulin-dependent diabetes, insulin-independent diabetes, 
coronary artery disease, stroke, hematologic diseases, au-
toimmune diseases, or any other condition reported to be 
associated with OSA were excluded, with the exception of 
patients with well-controlled hypertension. Further, any 
ocular disease other than retinal vascular occlusion and 
conditions compromising the capability of patients to un-
derstand or participate in the study were considered exclu-
sionary. 
All patients underwent full-night unattended level III 
polysomnography by means of a portable monitor Watch 
PAT-100 device (WP100; Itamar Medical, Caesarea, Israel). 
The WP100 is a Food and Drug Administration-approved 
portable diagnostic device for sleep apnea and is easy to 
use because the testing is done in the patient’s own bed-
room. This device is typically worn on the patient’s wrist, 
and there are two non-invasive, finger-mounted probes: a 
peripheral arterial tone (PAT) probe and a pulse oximeter 
(http://www.itamar-medical.com/). This device continu-
ously records on four channels: the PAT signal via a fin-
ger-mounted PAT probe, arterial oxygen saturation via fin-
ger-mounted pulse oximeter, sleep-wake state from the 
build-in actigraphic signal, and heart rate (derived from 
the PAT signal) [13]. The PAT signal measures the arterial 
pulsatile volume changes in the finger, which are regulated 
by ɑ-adrenergic innervation of the smooth muscles of its 
vasculature, and thus reflects sympathetic nervous system 
activity [13]. Because discrete obstructive airway events 
cause arousal from sleep and sympathetic activation, these 
events are associated with attenuation of the PAT signal 
[14]. On the following day, patients returned the WP100 
device, and the overnight polysomnographic data were up-
loaded and automatically analyzed using commercial soft-
ware (zzzPAT ver. 44, Itamar Medical). Despite the gold 
standard for an OSA diagnosis being the in-laboratory ap-
proach using level I polysomnography, the use of the 
WP100 has been validated to have reasonable reliability 
and specificity [13-15]. 
In addition to analyzing the PAT, heart rate and pulse 
oximetry data, the WP100 calculates three indices accord-
ing to the number of events per hour of sleep: the ap-
nea-hypopnea index (AHI), respiratory disturbance index 
(RDI) and oxygen desaturation index (ODI). The AHI is 
calculated as the average number of apnea and hypopnea 
events per hour of sleep; the RDI is determined based on 
the total number of apneas, hypopneas and respiratory ef-
fort-related arousals per hour of sleep, while the ODI is 
calculated as the number of oxygen desaturations of at 
least 4% from baseline per hour of sleep. An AHI of five 
or more events confirmed a positive OSA diagnosis. Cut-
off points of 5, 15 and 30 were used to indicate mild, mod-
erate and severe levels of OSA, respectively [16]. An RDI 
of five or more events was considered abnormally elevated. 
Records were accepted when patients had spent at least 6 
hours in bed and when good to excellent recordings of ar-
terial oxygen saturation and respiration were achieved. 
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We also evaluated the participants’ ophthalmic results, 
including the initial best-corrected visual acuity and the 
presence of a non-perfusion area larger than five disc di-
ameters on FA performed at least 6 months after the diag-
nosis of the BRVO. Moreover, we assessed patients’ snor-
ing behavior and incidence of daytime sleepiness or fatigue 
using the Berlin questionnaire.
Statistical analyses were performed using the SPSS ver. 
17.0 (SPSS Inc., Chicago, IL, USA). We compared patients 
both with and without OSA using the Fisher’s exact test for 
categorical data and the Mann-Whitney U-test for numeri-
cal data.
Results
This study included a total of 19 patients (6 males and 13 
females). Among these, 13 had no concurrent illness, in-
cluding hypertension, while six participants had well-con-
trolled hypertension. None of these patients had taken 
medication except for hypertension medication. The mean 
age of patients was 59.6 ± 9.4 years (range, 46 to 78 years). 
None of the patients were obese, and they all had a body 
mass index (BMI) of <30. Ten patients disclosed on the 
questionnaire that they snored during sleep, and four pa-
tients complained of excessive daytime sleepiness. Overall, 
42.1% of our patients (8 of 19) were found to have AHI 
values reflective of OSA, and 57.9% (11 of 19) were diag-
nosed with an abnormally elevated RDI (Table 1). Among 
the 13 patients who had no concurrent illness (including 
hypertension), the average AHI was 4.4 ± 5.9, with 30.8% 
of the patients (4 of 13) testing positive for OSA. Three of 
these patients were ranked as mild OSA, and one had mod-
erate OSA. For the patients with hypertension, the average 
AHI was found to be 10.4 ± 8.4, with 66.7% of the patients 
(4 of 6) testing positive for OSA: three with mild OSA and 
one with moderate OSA. 
Table 2 shows the results of a comparison within the 
groups both with and without OSA. There were no differ-
ences in age, sex, BMI, hypertension history, smoking his-
tory, and time (minutes) spent at less than 90% oxygen sat-
uration in the OSA and non-OSA groups. The OSA group 
had an average AHI of 12.3 ± 7.8, of which seven patients 
were ranked as mild OSA and two as moderate OSA. In 
the non-OSA group, the average AHI was found to be 2.0 
± 0.9. For all patients, AHI showed a positive correlation 
with RDI (γ = 0.587, p = 0.000), ODI (γ = 0.700, p = 0.000), 
minimal oxygen saturation (γ = -0.488, p = 0.005), and 4% 
to 9% desaturation times (γ = 0.752, p = 0.000). However, 
AHI had no signif icant correlation with patient age, 
weight, height, BMI, and time (minutes) spent at less than 
90% oxygen saturation.
We also analyzed the differences in ophthalmic exam-
inations within the OSA group and the non-OSA group. 
The initial visual acuity was not statistically different be-
tween the two groups. Although it was not statistically dif-
ferent, the OSA group contained relatively more patients 
with non-perfusion areas larger than five disc diameters on 
FA compared to the non-OSA group (75.0% vs. 36.4%).
Discussion
Several mechanisms by which OSA evokes RVO have 
been proposed. First, the change in retinal microcirculation 
caused by sleep apnea is related to the occurrence of RVO 
[11]. Respiratory events caused by OSA result in hypoxia, 
hypercapnia and activation of the sympathetic nervous 
system. Hypoxia-induced vasodilation of the central retinal 
artery can compress the adjacent central retinal vein and 
interfere with retinal blood f low. Hypercapnia-induced 
cerebral vasodilation can increase the intracranial and ce-
rebral spinal fluid pressure, inducing papilledema and ele-
vated venous pressure in the optic nerve head. This vaso-
dilation also has the effect of reducing the rate of retinal 
circulation. Moreover, activated sympathetic tone can also 
stimulate increases in arterial blood pressure. These three 
factors all impact hemodynamic changes in the retinal ar-
tery, which contribute to the occlusion of the retinal vein 
located in the same adventitial sheath and may help ex-
plain why RVO increases the incidence of OSA [11]. 
Second, the thrombogenicity of sleep apnea patients is 
another probable mechanism for the promotion of RVO in 
OSA [12]. Intermittent hypoxia produces reactive oxygen 
species and inflammatory cytokines (interleukin-6 and tu-
mor necrosis factor-ɑ), which increase the expression and 
release of tissue factors of vascular endothelial cells and 
trigger the extrinsic coagulation pathway and platelet ag-
gregation. Reactive oxygen species and inflammatory cy-
tokines also impair the repair capacity of endothelial cells 
and suppress fibrinolysis. All these factors may contribute 
to the hypercoagulable state frequently present in OSA 
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Table 1. Demographic characteristics and polysomnographic results of enrolled patients
Sex / age BMI HTN Smoking history AHI
OSA 
severity RDI ODI
<90% 
saturation 
time (min)
Minimal 
saturation 
(%)
 4% to 9%   
desaturation 
times
Initial VA
(logMAR)
NPA 
>5 DD
on FA
F / 46 26.4 Abs Abs 2.08 -   3.13 2.43 0.1 89 7 0.50 Pre
M / 76 22.7 Abs Abs  1.61 -   2.76 0.92 0.1 89 4 0.70 Pre
F / 65 21.2 Abs Abs  2.62 -   2.76 1.38 0 93 10 1.00 Abs
F / 53 22.7 Abs Abs  1.97 -   4.22 0.28 0 93 2 0.10 Abs
F / 51 23.5 Abs Abs  1.55 -  3.1 0.69 0 92 4 0.30 Abs
M / 50 26.8 Abs Pre  2.57 - 18.17 2.06 0.2 89 12 0.40 Abs
M / 50 25.3 Abs Pre  0.97 -  3.5 0.12 0 92 1 2.00 Pre
M / 54 21.8 Abs Abs 0.2 -  4.9 0 0 94 0 0.20 Abs
F / 68 25.9 Abs Abs 2.4 -  3.4 0 0 93 0 2.00 Pre
F / 68 23.7 Abs Abs  5.71 Mild  7.7 3.42 0.1 89 12 1.50 Pre
F / 64 24.3 Abs Abs  5.63 Mild  8.09 2.11 0 91 6 0.30 Pre
F / 66 21.0 Abs Abs 7.7 Mild 11.6 3 0 91 11 1.00 Abs
F / 60 22.9 Abs Abs 22.82 Moderate 23.04 9.13 0.8 85 40 1.00 Pre
F / 53 25.0 Pre Abs 2.86 -  9.09 1.56 0 92 6 1.70 Abs
M / 66 19.9 Pre Pre 3.33 -  5.36 2.17 0 90 15 1.00 Abs
F / 60 27.3 Pre Abs 6.25 Mild 7.4 2.68 0.4 89 21 0.20 Abs
F / 56 26.6 Pre Abs 10.45 Mild 11.43 6.2 1 83 34 0.20 Pre
M / 48 27.0 Pre Abs 14.8 Mild 21.5 6.52 0 90 37 0.40 Pre
F / 78 25.6 Pre Abs 25 Moderate 25.7 19.2 1.9 87 133 0.70 Pre
BMI = body mass index; HTN = hypertension; AHI = apnea-hypopnea index; OSA = obstructive sleep apnea; RDI = respiratory distur-
bance index; ODI = oxygen desaturation index; VA = visual acuity; logMAR = logarithm of the minimum angle of resolution; NPA = 
non-perfusion area; DD = disc diameter; FA = fluorescein angiography; Abs = absence; Pre = presence.
Table 2. Demographic data for patients with OSA and for those without OSA
OSA group (n = 8) Non-OSA group (n = 11) p-value
Age (yr) 62.5 ± 8.9 57.5 ± 9.6 0.272
Sex (female : male) 7 : 1 6 : 5 0.153
Body mass index 24.8 ± 2.2 23.7 ± 2.3 0.272
Hypertension (yes : no) 4 : 4 2 : 9 0.166
Smoking history (yes : no) 0 : 8 3 : 8 0.170
Apnea-hypopnea index 12.3 ± 7.8 2.0 ± 0.9 0.000*
Respiratory disturbance 14.6 ± 7.6 5.6 ± 4.8 0.002*
Oxygen desaturation index  6.2 ± 5.9 1.1 ± 0.9 0.003*
Saturation <90% time (min) 0.53 ± 0.68 0.04 ± 0.07 0.091
Minimal saturation (%) 88.1 ± 2.9 91.5 ± 1.9 0.012*
4% to 9% desaturation times 36.8 ± 41.0 5.5 ± 5.0 0.002*
Initial logMAR VA 0.7 ± 0.5 0.9 ± 0.7 0.545
NPA >5 DD (yes : no) 6 : 2 4 : 7 0.115
OSA = obstructive sleep apnea; logMAR = logarithm of the minimum angle of resolution; VA = visual acuity; NPA = non-perfusion 
area; DD = disc diameter.
*p < 0.05.
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and are able to trigger RVO [12]. 
In this prospective consecutive study, we found that the 
rate of OSA was high in BRVO patients (42.1% in all 
BRVO patients and 30.8% in BRVO patients without sys-
temic diseases). It was significantly higher than the overall 
prevalence of OSA in the normal, middle-aged Korean 
population (male, 4.5%; female, 3.2%) [17]. The rate of 
OSA in RVO patients in this study was comparable to that 
of a previous study by Glacet-Bernard et al. [11], which re-
ported an OSA prevalence of 37% in RVO patients. We 
found the rate of OSA in BRVO patients without any dis-
ease to be high. These results were obtained despite the 
exclusion of BRVO patients with concomitant diseases be-
sides hypertension; therefore, the prevalence of OSA in all 
BRVO patients may be much higher.
As mentioned above, previous studies have shown an as-
sociation between RVO and OSA [11,12]. However, they 
did not use any exclusion criteria, and their investigations 
included both branch and central RVO patients. Because 
branch and central RVO have different mechanisms of 
pathogenesis, it will be worthwhile to evaluate the preva-
lence of OSA in each subtype. It would also be valuable to 
investigate patients with no systemic disease because the 
inclusion of patients with many systemic diseases could 
confound the impact of OSA in BRVO since other system-
ic diseases also act as risk factors for BRVO. Our current 
study is the first to evaluate the prevalence of OSA in a se-
ries of BRVO patients with no concomitant, OSA-associat-
ed diseases. 
Although it was not statistically proven, we found that 
OSA patients would have experienced a more severe form 
of BRVO. In addition, 75.0% of the OSA group had a 
non-perfusion area greater than five disc diameters on FA 
performed at least 6 months after the diagnosis of the 
BRVO, in comparison to 36.4% in non-OSA patients. This 
result may have occurred because OSA patients experience 
more hypoxia events during sleep. However, further clini-
cal studies using a larger cohort of patients will be needed 
to assess whether OSA affects the clinical manifestation of 
BRVO and whether OSA treatment could improve the vi-
sual outcome in BRVO.
The major limitations of this study were the small num-
ber of enrolled patients and the lack of a control group. 
The results were based on a single-night measurement 
with a portable device. We were unable to calculate the ex-
act prevalence of OSA in BRVO patients using this study 
alone. Therefore, this result must be regarded as prelimi-
nary. Further study with a control group will be needed to 
determine whether the prevalence of OSA is higher in 
BRVO patients and also to show the differences of the 
OSA indices between BRVO patients and a normal popu-
lation. 
This was a preliminary study that was conducted to in-
vestigate the prevalence of OSA in BRVO patients without 
certain risk factors. This study included 19 participants 
and suggested that OSA is common in BRVO patients 
(42.1%). Especially, we found a higher than expected rate 
of OSA (30.8%) in 13 BRVO patients without any other 
systemic risk factors. Our findings suggest that OSA could 
be an additional risk factor in the pathogenesis of BRVO 
or at least a frequently associated condition that could 
function as a triggering factor. However, further study 
with a control group and a large study population is need-
ed to determine whether the prevalence of OSA is higher 
in BRVO patients.
As retinal specialists, we encounter many BRVO pa-
tients that do not exhibit any obvious risk factors for OSA. 
However, our findings suggest that OSA could be a risk 
factor in the pathogenesis of BRVO in patients with no 
concomitant diseases, such as hypertension and diabetes. 
Even if it is not an additional independent risk factor per 
se, OSA may represent a frequently associated condition 
that functions as a triggering factor for BRVO. Therefore, 
it is vital to recognize OSA in those with BRVO as a meth-
od to ensure the general health of the patient.
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